T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study
Kidney transplantation (KT) is the current treatment of choice in patients with end-stage kidney disease. Immunosuppression is required to prevent acute rejection but is associated with a high incidence of adverse events. The immunosuppressive burden substantially differs between individuals, necess...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Transplant International |
| Subjects: | |
| Online Access: | https://www.frontierspartnerships.org/articles/10.3389/ti.2025.14443/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839626648647892992 |
|---|---|
| author | Simon Aberger Simon Aberger Max Schuller Agnes A. Mooslechner Agnes A. Mooslechner Konstantin A. Klötzer Barbara Prietl Barbara Prietl Verena Pfeifer Verena Pfeifer Alexander H. Kirsch Alexander R. Rosenkranz Katharina Artinger Kathrin Eller |
| author_facet | Simon Aberger Simon Aberger Max Schuller Agnes A. Mooslechner Agnes A. Mooslechner Konstantin A. Klötzer Barbara Prietl Barbara Prietl Verena Pfeifer Verena Pfeifer Alexander H. Kirsch Alexander R. Rosenkranz Katharina Artinger Kathrin Eller |
| author_sort | Simon Aberger |
| collection | DOAJ |
| description | Kidney transplantation (KT) is the current treatment of choice in patients with end-stage kidney disease. Immunosuppression is required to prevent acute rejection but is associated with a high incidence of adverse events. The immunosuppressive burden substantially differs between individuals, necessitating new immune monitoring strategies to achieve personalization of immunosuppression. To compare the evolution of T cell profiles in correlation with immunosuppression and clinical outcomes, 87 kidney transplant recipients were followed for 12 months after KT. Flow cytometry along with assessment of T cell activation markers and clinical data was performed before KT and during study visits 10 days, 2 months and 12 months after KT. Longitudinal T cell phenotyping revealed a significant decrease of T cell activation markers HLA-DR, FCRL3, and CD147 in CD4+ effector T cells after KT. The most pronounced reduction (75%) was found for the activation-proliferation marker HLA-DR, which persisted throughout the observational period. The decrease in HLA-DR expression reflected immunosuppressive burden through strong associations with tacrolimus trough-level exposure (coeff = −0.39, p < 0.01) and BK viremia incidence (coeff = −0.40, p < 0.01) in multivariable regression analysis. T cell activation marker HLA-DR emerges as a potential biomarker for tacrolimus-related immunosuppressive burden in association with BK viremia risk following KT. |
| format | Article |
| id | doaj-art-d7a6df6098f1487e9f4ece4932e0928d |
| institution | Matheson Library |
| issn | 1432-2277 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Transplant International |
| spelling | doaj-art-d7a6df6098f1487e9f4ece4932e0928d2025-07-17T05:10:05ZengFrontiers Media S.A.Transplant International1432-22772025-07-013810.3389/ti.2025.1444314443T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort StudySimon Aberger0Simon Aberger1Max Schuller2Agnes A. Mooslechner3Agnes A. Mooslechner4Konstantin A. Klötzer5Barbara Prietl6Barbara Prietl7Verena Pfeifer8Verena Pfeifer9Alexander H. Kirsch10Alexander R. Rosenkranz11Katharina Artinger12Kathrin Eller13Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaDepartment of Internal Medicine I, Nephrology, Paracelsus Medical University, Salzburg, AustriaDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaOtto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, AustriaDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaCenter for Biomarker Research in Medicine, Graz, AustriaDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaCenter for Biomarker Research in Medicine, Graz, AustriaDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaKidney transplantation (KT) is the current treatment of choice in patients with end-stage kidney disease. Immunosuppression is required to prevent acute rejection but is associated with a high incidence of adverse events. The immunosuppressive burden substantially differs between individuals, necessitating new immune monitoring strategies to achieve personalization of immunosuppression. To compare the evolution of T cell profiles in correlation with immunosuppression and clinical outcomes, 87 kidney transplant recipients were followed for 12 months after KT. Flow cytometry along with assessment of T cell activation markers and clinical data was performed before KT and during study visits 10 days, 2 months and 12 months after KT. Longitudinal T cell phenotyping revealed a significant decrease of T cell activation markers HLA-DR, FCRL3, and CD147 in CD4+ effector T cells after KT. The most pronounced reduction (75%) was found for the activation-proliferation marker HLA-DR, which persisted throughout the observational period. The decrease in HLA-DR expression reflected immunosuppressive burden through strong associations with tacrolimus trough-level exposure (coeff = −0.39, p < 0.01) and BK viremia incidence (coeff = −0.40, p < 0.01) in multivariable regression analysis. T cell activation marker HLA-DR emerges as a potential biomarker for tacrolimus-related immunosuppressive burden in association with BK viremia risk following KT.https://www.frontierspartnerships.org/articles/10.3389/ti.2025.14443/fullimmune monitoringimmunosuppressionkidney transplantationtranslational nephrologypersonalized medicine |
| spellingShingle | Simon Aberger Simon Aberger Max Schuller Agnes A. Mooslechner Agnes A. Mooslechner Konstantin A. Klötzer Barbara Prietl Barbara Prietl Verena Pfeifer Verena Pfeifer Alexander H. Kirsch Alexander R. Rosenkranz Katharina Artinger Kathrin Eller T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study Transplant International immune monitoring immunosuppression kidney transplantation translational nephrology personalized medicine |
| title | T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study |
| title_full | T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study |
| title_fullStr | T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study |
| title_full_unstemmed | T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study |
| title_short | T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study |
| title_sort | t cell activation marker hla dr reflects tacrolimus associated immunosuppressive burden and bk viremia risk after kidney transplantation an observational cohort study |
| topic | immune monitoring immunosuppression kidney transplantation translational nephrology personalized medicine |
| url | https://www.frontierspartnerships.org/articles/10.3389/ti.2025.14443/full |
| work_keys_str_mv | AT simonaberger tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT simonaberger tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT maxschuller tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT agnesamooslechner tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT agnesamooslechner tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT konstantinaklotzer tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT barbaraprietl tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT barbaraprietl tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT verenapfeifer tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT verenapfeifer tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT alexanderhkirsch tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT alexanderrrosenkranz tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT katharinaartinger tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy AT kathrineller tcellactivationmarkerhladrreflectstacrolimusassociatedimmunosuppressiveburdenandbkviremiariskafterkidneytransplantationanobservationalcohortstudy |